Buscar
Mostrando ítems 21-30 de 48
ANTIVIRAIS DE AÇÃO DIRETA NO TRATAMENTO DA HEPATITE C: FATORES ASSOCIADOS COM A RESPOSTA VIROLÓGICA
(Universidade Federal de Santa Maria, 2022)
Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients
(2017)
Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated ...
Sofosbuvir terminated RNA is more resistant to SARS‐CoV‐2 proofreader than RNA terminated by Remdesivir
SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a hundred years.
After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing
hepatitis C virus ...
Clinical and epidemiological profile of genotype 3 HCV patients in the South of Brazil
(HCPA/FAMED/UFRGS, 2020)
Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro
(2014)
Compounds extracted from plants can provide an alternative approach to new therapies. They present characteristics such as high chemical diversity, lower cost of production and milder or inexistent side effects compared ...
Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.
(2017)
Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated ...
Efeito dos Antivirais de Ação Direta nos parâmetros bioquímicos da Síndrome Metabólica em pessoas com hepatite C
(Universidade Federal de Santa Maria, 2021)
Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney diseaseEficacia y seguridad de los antivíricos de acción directa para el VHC en la nefropatía crónica de leve a moderada
(Sociedad Española de Nefrología Dr Rafael Matesanz, 2019-06)
BACKGROUND AND AIMS:The advent of direct-acting antiviral agents promises to change the management of hepatitis C virus infection (HCV) in patients with chronic kidney disease (CKD), a patient group in which the treatment ...